Macquarie Group
BDTX icon

Macquarie Group’s Black Diamond Therapeutics BDTX Stock Holding History

Macquarie Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,182
Closed -$6 – 1924
2024
Q1 		$6 Buy
+1,182
New +$4.77K ﹤0.01% 1764
2021
Q4 		– Sell
-173
Closed -$1K – 2604
2021
Q3 		$1K Hold
173
– – ﹤0.01% 2619
2021
Q2 		$2K Sell
173
-30,208
-99% -$597K ﹤0.01% 2542
2021
Q1 		$737K Buy
30,381
+4,322
+17% +$117K ﹤0.01% 1462
2020
Q4 		$835K Buy
26,059
+2,433
+10% +$79.9K ﹤0.01% 1350
2020
Q3 		$715K Buy
23,626
+23,371
+9,165% +$711K ﹤0.01% 1321
2020
Q2 		$11K Buy
+255
New +$9.38K ﹤0.01% 2274

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's BDTX Position: Q2 2024 in Review

Macquarie Group sold out of Black Diamond Therapeutics (BDTX) in Q2 2024, closing a stake of 1,182 shares — an estimated $6 sold.

Macquarie Group first reported a position in BDTX in Q2 2020 and held it in 7 quarters. The position peaked at $835K in Q4 2020. 90 funds tracked by Wall St. Rank hold BDTX as of Q2 2024.

  • Macquarie Group reported no remaining Black Diamond Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 1,182 Black Diamond Therapeutics shares in Q2 2024, an estimated $6.
  • Macquarie Group first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 7 quarters.
  • Macquarie Group's Black Diamond Therapeutics position peaked at $835K in Q4 2020.
  • 90 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.